Halozyme Therapeutics (HALO) EBIT Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 89.72% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 44.54% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -26.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -18.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 44.34% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 81.27% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 44.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.95% |
| Mar 31, 2026 | 50.80% |
| Dec 31, 2025 | -48.07% |
| Sep 30, 2025 | 37.79% |
| Jun 30, 2025 | 81.14% |
| Mar 31, 2025 | 23.21% |
| Dec 31, 2024 | 45.88% |
| Sep 30, 2024 | 29.25% |
| Jun 30, 2024 | 8.01% |
| Mar 31, 2024 | 23.49% |
| Dec 31, 2023 | 9.18% |
| Sep 30, 2023 | 29.87% |
| Jun 30, 2023 | 47.30% |
| Mar 31, 2023 | 165.40% |
| Dec 31, 2022 | 62.91% |
| Sep 30, 2022 | 75.38% |
| Jun 30, 2022 | 64.32% |
| Mar 31, 2022 | 194.39% |
| Dec 31, 2021 | 827.64% |
| Sep 30, 2021 | 70.62% |